Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Attr Amyloidosis Wild Type Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Attr Amyloidosis Wild Type. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Attr Amyloidosis Wild Type clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 / Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Steen Hvitfeldt Poulsen (1), Helse Møre og Romsdal HF (1), Columbia University (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Dobutrex (drug, 1 trial), followed by Tc99-PYP or Tc99-HDMP Scan.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
4
Sponsors

Track Attr Amyloidosis Wild Type trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1 / Phase 2NCT06318260

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt). The main...

Sponsor: Steen Hvitfeldt PoulsenEnrolling: 151 location
RECRUITINGNCT06458374

ATTR Cardiac Amyloidosis in a Selected Population

Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be...

Sponsor: Helse Møre og Romsdal HFEnrolling: 1801 location
RECRUITINGNCT06034405

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Primary objective: To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are...

Sponsor: Columbia UniversityEnrolling: 16636 locations
RECRUITINGNCT06836011

A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence,...

The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral...

Sponsor: Medical University of ViennaEnrolling: 6008 locations

Frequently Asked Questions

There are currently 4 clinical trials for Attr Amyloidosis Wild Type, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Attr Amyloidosis Wild Type, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Attr Amyloidosis Wild Type, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.